Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
about
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelorTicagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromesDual antiplatelet therapy: optimal timing, management, and durationCoronary revascularization in the elderly with stable anginaTicagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agentPharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Management standards for stable coronary artery disease in India.German nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life.Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.Measurement of platelet aggregation, independently of patient platelet count: a flow-cytometric approach.The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosisWarm winter is associated with low incidence of ST elevation myocardial infarctions and less frequent acute coronary angiographies in an alpine country.Interaction between access choice and pharmacotherapy for coronary intervention: the results of a UK survey.Southern Saskatchewan Ticagrelor Registry experience.Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application.Antiplatelet combinations for prevention of atherothrombotic eventsBleeding risk stratification in an era of aggressive management of acute coronary syndromesTicagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.An overview of PCI in the very elderlyPercutaneous treatment in acute coronary syndromes.Current antiplatelet treatment strategy in patients with diabetes mellitus.Critical appraisal of ticagrelor in the management of acute coronary syndromePrimary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisAntiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Possible Therapeutic Effect of Stem Cell in Atherosclerosis in Albino Rats. A Histological and Immunohistochemical Study.Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication.Percutaneous coronary intervention in nonagenarians: pros and cons.Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorIncidence, Time Trends, and Predictors of Intracranial Hemorrhage During Long-Term Follow-up After Acute Myocardial InfarctionSystematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndromeRisk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetesAlmanac 2011: Acute Coronary Syndromes. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi
P2860
Q24605508-AA3DF4FC-AE17-4691-80B2-B84AA3DAD925Q24631111-16DC3E17-CA50-44DC-BF3C-C2B99638EDFDQ26741055-F67DE9D3-64CD-4BEE-A68C-6F0E6C656634Q26778104-A081848A-745C-442C-844E-5BB2FF9A628CQ26829967-B0D62184-061E-40B0-B6CA-87E9D6991D31Q27022443-2A3BE45C-62F0-4A88-B1AA-6B5BEDC830E6Q30239853-F1AEFD37-EC53-46A5-BD53-FD8629CAF5CEQ30761633-46E7E0B3-5F64-4F6E-93FA-50A89BA33BC6Q33393888-1DD76E1F-BEC7-445C-87BF-5E5E402DAD19Q33440160-49878E47-574C-4769-81F7-DC3641A6AB7CQ33699370-F84F92D8-2FAF-4686-A54A-C2DB1E15694DQ34043989-AF85A4DC-5E08-4E82-8B7E-209E6F66856CQ34276408-F54A4F2A-40FB-4CF4-9B68-CE5B02F8B800Q34303562-6221C8C8-A098-47EA-ABF3-050057CC94C3Q34333287-03108E8F-AFB4-40C3-9340-0045DA4EE451Q34387201-9B402659-378E-4043-B5E8-72A221E8E1DAQ34554918-2941CE3F-12BA-454C-9EFE-FB45A7DBDA89Q34566264-FC9D6EEF-1119-4F52-9DD9-40C54CD4A552Q34574018-C853172F-39A7-439B-9BBB-E05B811BE776Q34805121-06D90E89-CB01-4258-8DD4-F43C401C8335Q35048557-F4780DBF-678A-4F84-B5AA-96D7E721F318Q35051753-290053A2-4E95-4634-A59D-E71EE01138E6Q35378992-34DC9E37-E2E8-42C7-837E-E6EE4A816FE5Q35510430-124C5698-3CFE-4AD8-8980-C3A2DB3C6D4FQ35544048-B1EF8B3F-65CD-4CAD-984D-03BE1426D6FFQ35660767-422A1492-4948-46AF-9A17-6C5ADF462662Q35752598-CC9C59FA-2D1D-473D-BD82-C5B8F8BE6C3DQ36062323-C51B224B-7FA0-4C8F-A51D-561606DAACB0Q36160606-BB45E37C-A61F-4E3A-8722-1CFBBAE7A630Q36295489-040B7C35-6F77-455D-9D78-19F23AA03169Q36709028-8A6492A1-8A91-44FE-BA66-91FC59F34071Q36769847-3BEE7B76-1A54-44FA-B219-972858C073EAQ36807413-52C76982-413D-45C5-AE1D-E6B4721EF416Q36836368-E22A6885-E3CE-490D-9F03-83578711E2F3Q36841959-FC764FF6-1617-49F8-AAED-922E6D28F97DQ36995923-05461171-DCC1-4727-A3FD-EA0B2AD43F0CQ37022618-BC70FA04-2EAC-4C43-ADA8-23D7608AF05DQ37066826-BB90B3EB-DEF5-47F1-B064-BBFE8453C061Q37221845-740B2AC1-1DE2-45BE-B595-C60FC0B1A9D2Q37412869-B466691F-2F3C-4420-9E88-470391F5FAD7
P2860
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparison of ticagrelor with ...... randomised double-blind study.
@ast
Comparison of ticagrelor with ...... randomised double-blind study.
@en
Comparison of ticagrelor with ...... y for acute coronary syndromes
@nl
type
label
Comparison of ticagrelor with ...... randomised double-blind study.
@ast
Comparison of ticagrelor with ...... randomised double-blind study.
@en
Comparison of ticagrelor with ...... y for acute coronary syndromes
@nl
prefLabel
Comparison of ticagrelor with ...... randomised double-blind study.
@ast
Comparison of ticagrelor with ...... randomised double-blind study.
@en
Comparison of ticagrelor with ...... y for acute coronary syndromes
@nl
P2093
P50
P1433
P1476
Comparison of ticagrelor with ...... randomised double-blind study.
@en
P2093
Basil S Lewis
Christopher P Cannon
Daniel Wojdyla
Diego Ardissino
Frederic Kontny
Hugo Katus
Matyas Keltai
Nardev S Khurmi
PLATelet inhibition and patient Outcomes Investigators
Richard C Becker
P304
P356
10.1016/S0140-6736(09)62191-7
P407
P577
2010-01-13T00:00:00Z